Diabetes appears to be linked with an increased risk of pelvic girdle syndrome. This is shown in a new study from the Norwegian Institute of Public Health and Akershus University Hospital. The study showed that five percent of women had had serious pelvic girdle syndrome (pain in both iliosacral ligaments and symphysis pubis) during their
Full Post: Pelvic girdle syndrome linked to diabetes
Schering-Plough Corporation has announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter for SAPHRIS (asenapine) sublingual tablets in the acute treatment of schizophrenia in adults and in the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults as monotherapy.
The action letter includes proposed labeling for both indications and a request for supplemental data from the existing asenapine database. No additional clinical trials have been requested. The Company anticipates providing the requested information to the agency in the first quarter of 2009.
“We are pleased with the progress on the SAPHRIS filing and look forward to working with the agency to address its request, finalize the product labeling and gain approval,” said Thomas P. Koestler, Ph.D., executive vice president and president, Schering-Plough Research Institute. “New treatments are needed in this therapeutic area and we believe that asenapine has the potential to be an important option in addressing this need.”
Schering-Plough acquired asenapine in November 2007 through its acquisition of Organon BioSciences, which developed the antipsychotic agent. The New Drug Application (NDA) for asenapine includes data from a clinical trial program involving more than 3,000 patients in schizophrenia and bipolar mania trials.
http://www.schering-plough.com/
--------------------------------------------------------------------------------------------
Related Posts:
Schizophrenia and bipolar disorder have for decades been regarded as two distinct psychotic disorders when it comes to definitions and risk factors. Schizophrenia is a psychotic illness that causes delusions and hallucinations - bipolar disorder also known as manic depression, causes extreme mood swings from deep depression to manic episodes. But now a study by
Full Post: Schizophrenia and bipolar disorder have same genetic causes
Caraco Pharmaceutical Laboratories, Ltd. announced today that it has timely submitted its response to the FDA warning letter that was received on October 31, 2008. In the warning letter, the FDA requested a response from Caraco within 15 business days, ending November 24, 2008. As previously disclosed, the warning letter was issued as a follow
Full Post: Caraco Pharmaceutical Labs responds to FDA warning
During heart failure the body reacts to the production of the hormone aldosterone. Too much aldosterone can stiffen and damage the muscles of the heart. Dutch researcher Luc Roumen has optimised compounds that inhibit the production of this hormone and looked at their optimum dosage. The compounds were manufactured by the companies Schering-Plough and
Full Post: New therapy for heart failure
Eli Lilly and Company has announced that it received a complete response letter from the U.S. Food and Drug Administration (FDA) for olanzapine long-acting injection (LAI) for acute and maintenance treatment of schizophrenia in adults. Lilly is continuing to work with the agency on the new drug application (NDA). The FDA does not require any
Full Post: Lilly receives complete response letter for Olanzapine LAI for treatment of schizophrenia
Centocor, Inc., has announced that the U.S. Food and Drug Administration (FDA) issued a Complete Response letter for its Biologics License Application (BLA) for ustekinumab. The application, filed by Centocor in late 2007, seeks approval to market ustekinumab as a subcutaneous biologic therapy for the treatment of adult patients with chronic moderate to severe plaque
Full Post: FDA issues complete response to biologics license application for ustekinumab --------------------------------------------------------------------------------------------
